{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:25Z","timestamp":1787840425504,"version":"build-2784847793"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.4103\/idoj.idoj_353_23","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:19:36Z","timestamp":1714393176000},"page":"546-548","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-Induced Hypertrophic Lichenoid Dermatitis and Bullous Pemphigoid in One Patient"],"prefix":"10.4103","volume":"15","author":[{"given":"Manal","family":"Alsabbagh","sequence":"first","affiliation":[{"name":"Department of Dermatology, King Hamad University Hospital, Busaiteen, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Bava","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King Hamad University Hospital, Busaiteen, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Pathology, King Hamad University Hospital, Busaiteen, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","DOI":"10.1177\/1756287219839285","article-title":"Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: Clinical trial evidence and experience","volume":"11","author":"Crist","year":"2019","journal-title":"Ther Adv Urol"},{"key":"R2-20250921","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ccr3.2090","article-title":"Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient","volume":"7","author":"Honigman","year":"2019","journal-title":"Clin Case Rep"},{"key":"R4-20250921","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1111\/jdv.14179","article-title":"Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology","volume":"31","author":"Bandino","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2020.09.032","article-title":"How to manage patients with corticosteroids in oncology in the era of immunotherapy?","volume":"141","author":"Aldea","year":"2020","journal-title":"Eur J Cancer"},{"key":"R7-20250921","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20250921","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","article-title":"Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"145","author":"Skribek","year":"2021","journal-title":"Eur J Cancer"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"1175809","DOI":"10.3389\/fimmu.2023.1175809","article-title":"Immune-related adverse events associated with nab-paclitaxel\/paclitaxel combined with immune checkpoint inhibitors: A systematic review and network meta-analysis","volume":"14","author":"Hao","year":"2023","journal-title":"Front Immunol"},{"key":"R10-20250921","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.annonc.2020.09.012","article-title":"Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: Interim results of the open-label, single-arm, phase II PEANUT study","volume":"31","author":"Giannatempo","year":"2020","journal-title":"Ann Oncol"},{"key":"R11-20250921","doi-asserted-by":"crossref","first-page":"e31940","DOI":"10.1097\/MD.0000000000031940","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials","volume":"101","author":"Swed","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R12-20250921","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R13-20250921","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cup.13739","article-title":"Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma","volume":"47","author":"Marques-Piubelli","year":"2020","journal-title":"J Cutan Pathol"},{"key":"R14-20250921","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/cia2.12179","article-title":"Hypertrophic lichenoid dermatitis during pembrolizumab treatment","volume":"4","author":"Honda","year":"2021","journal-title":"Journal of Cutaneous Immunology and Allergy"},{"key":"R15-20250921","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/cup.13454","article-title":"Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+and CD16+monocytes driving an innate immune response","volume":"46","author":"Curry","year":"2019","journal-title":"J Cutan Pathol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_353_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:18Z","timestamp":1787836938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_353_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_353_23","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"2023-05-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}